Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, Non-Hodgkin

Explore clinical trials studying Lymphoma, Non-Hodgkin. Study availability and eligibility vary by location and protocol.

2,778 public trials 699 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, Non-Hodgkin trial results

Completed

Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma

NCT03846427

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • Clinical Research Alliance, Inc Westbury, New York, United States
  • The Charlotte Mecklenburg Hospital Authority Charlotte, North Carolina, United States
  • Canberra Hospital Garran, Australian Capital Territory, Australia
  • Concord Repatriation General Hospital Concord, New South Wales, Australia
View all 31 locations
View Trial Details
Completed

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

NCT03493451

Conditions
ALK-Positive Anaplastic Large Cell Lymphoma, ALK-negative Anaplastic Large Cell Lymphoma, Adult Nasal Type Extranodal NK/T-cell Lymphoma, +36 more
Locations
  • British Columbia Cancer Agency the Vancouver Centre Vancouver, British Columbia, Canada
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Beijing Hospital Beijing, Beijing Municipality, China
  • Peking Union Medical College Hospital Beijing, Beijing Municipality, China
View all 24 locations
View Trial Details
Completed

Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

NCT03206970

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Beijing Cancer Hospital Beijing, Beijing Municipality, China
  • Fujian Medical University Union Hospital Fuzhou, Fujian, China
  • Nanfang Hospital of Southern Medical University Guangzhou, Guangdong, China
  • Henan Cancer Hospital Zhengzhou, Henan, China
View all 13 locations
View Trial Details
Completed

BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)

NCT03520920

Conditions
Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Hemic and Lymphatic Diseases, +13 more
Locations
  • Harbin Medical University Cancer Hospital Harbin, Heilongjiang, China
  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology Wuhan, Hubei, China
  • The Affiliated Hospital of Xuzhou Medical University Xuzhou, Jiangsu, China
  • Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai, Shanghai Municipality, China
View Trial Details
Completed

Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma

NCT03145064

Conditions
Diffuse Large B-cell Lymphoma, Disease Attributes, Hemic and Lymphatic Diseases, +13 more
Locations
  • Beijing Cancer Hospital Beijing, Beijing Municipality, China
  • Harbin Medical University Cancer Hospital Harbin, Heilongjiang, China
  • Henan Cancer Hospital Zhengzhou, Henan, China
  • The First Affiliated Hospital of Soochow University Branch Shizi Suzhou, Jiangsu, China
View Trial Details
Completed

Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)

NCT04434937

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • Ja-Aichi Anjo Kosei Hospital Anjo, Japan
  • University of Fukui Hospital Fukui, Japan
  • Jcho Kyushu Hospital Fukuoka, Japan
  • National Hospital Organization Kyushu Cancer Center Fukuoka, Japan
View all 30 locations
View Trial Details
Completed

Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

NCT03340766

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • Research Site La Jolla, California, United States
  • Research Site Charleston, South Carolina, United States
  • Research Site Greenville, South Carolina, United States
  • Research Site Darlinghurst, New South Wales, Australia
View all 22 locations
View Trial Details

Related conditions